60.34 USD
-0.97 (-1.58%)
We assign a fundamental rating of 6 out of 10 to BMRN. BMRN was compared to 530 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
BMRN had a positive operating cash flow in the past year.
Of the past 5 years BMRN 4 years were profitable.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.64% of its industry peers.
BMRN has a Return On Equity of 8.59%. This is amongst the best in the industry. BMRN outperforms 92.08% of its industry peers.
BMRN has a better Return On Invested Capital (7.69%) than 93.96% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.28%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a better Profit Margin (16.82%) than 92.64% of its industry peers.
Looking at the Operating Margin, with a value of 20.21%, BMRN belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
BMRN's Gross Margin of 81.32% is amongst the best of the industry. BMRN outperforms 85.28% of its industry peers.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
BMRN has more shares outstanding than it did 1 year ago.
BMRN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 5.73. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BMRN (5.73) is better than 73.58% of its industry peers.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
BMRN has a Debt to FCF ratio of 0.72. This is amongst the best in the industry. BMRN outperforms 94.53% of its industry peers.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, BMRN is doing worse than 62.26% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.73 |
ROIC/WACC0.92
WACC8.33%
2.3 Liquidity
A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Current ratio (4.83) which is in line with its industry peers.
A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
The Quick ratio of BMRN (3.10) is worse than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.34% on average per year.
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y27.59%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 22.68 indicates a rather expensive valuation of BMRN.
94.34% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (26.92), we can say BMRN is valued inline with the index average.
A Price/Forward Earnings ratio of 13.39 indicates a correct valuation of BMRN.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 96.79% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.57, BMRN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.68 | ||
| Fwd PE | 13.39 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.91% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 97.55% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.04 | ||
| EV/EBITDA | 15.07 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
BMRN's earnings are expected to grow with 35.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.64
PEG (5Y)N/A
EPS Next 2Y42.79%
EPS Next 3Y35.49%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BMRN (1/8/2026, 11:43:08 AM)
60.34
-0.97 (-1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.82%
Inst Owner Change0%
Ins Owners0.64%
Ins Owner Change-0.62%
Market Cap11.59B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts82.35
Price Target92.08 (52.6%)
Short Float %4.25%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.16%
PT rev (3m)-5.43%
EPS NQ rev (1m)-3.95%
EPS NQ rev (3m)8.36%
EPS NY rev (1m)1.38%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.68 | ||
| Fwd PE | 13.39 | ||
| P/S | 3.75 | ||
| P/FCF | 14.04 | ||
| P/OCF | 12.68 | ||
| P/B | 1.91 | ||
| P/tB | 2.06 | ||
| EV/EBITDA | 15.07 |
EPS(TTM)2.66
EY4.41%
EPS(NY)4.51
Fwd EY7.47%
FCF(TTM)4.3
FCFY7.12%
OCF(TTM)4.76
OCFY7.88%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.64
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.73 |
F-Score8
WACC8.33%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y41.21%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 35.7% in the next year.